The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 27, 2016

Filed:

Aug. 22, 2011
Applicants:

Sunil Shaunak, Greater London, GB;

Ian Alfred Teo, Greater London, GB;

Inventors:

Sunil Shaunak, Greater London, GB;

Ian Alfred Teo, Greater London, GB;

Assignee:

IMPERIAL INNOVATIONS LIMITED, London, Greater London, GB;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A01N 43/04 (2006.01); A61K 31/70 (2006.01); A61K 31/715 (2006.01); C08B 37/00 (2006.01); C07G 3/00 (2006.01); C07G 11/00 (2006.01); C07H 15/00 (2006.01); C07H 17/00 (2006.01); C07H 15/26 (2006.01); A61K 47/48 (2006.01); C07H 5/06 (2006.01); C07H 11/00 (2006.01); C07H 13/04 (2006.01); C08G 73/02 (2006.01); C07H 15/12 (2006.01); C08G 83/00 (2006.01);
U.S. Cl.
CPC ...
C07H 15/26 (2013.01); A61K 47/48192 (2013.01); A61K 47/48207 (2013.01); C07H 5/06 (2013.01); C07H 11/00 (2013.01); C07H 13/04 (2013.01); C07H 15/12 (2013.01); C08G 73/02 (2013.01); C08G 73/024 (2013.01); C08G 73/028 (2013.01); C08G 83/003 (2013.01);
Abstract

A glycodendrimer comprising: a) a non-toxic dendrimer polypropyletherimine core supporting on average in the range of 9 to 64 terminal carboxylic acid groups, and b) conjugated to said core in the range of 2 to 8 amino sugars or a sulphate amino sugar selected from the group consisting of glucosamine, N-acetyl glucosamine, mannosamine, N-acetylmannosamine, galactosamine, a sulphate of any one of the same and a combination thereof, wherein each sugar is linked directly through a zero length amide bond with a residue of a terminal carboxylic acid group. The invention also extends to defined populations comprising said glycodendrimer molecules, pharmaceutical compositions comprising said molecules or populations, process for preparing the molecules and formulations, and therapeutic uses of the molecules, populations and compositions.


Find Patent Forward Citations

Loading…